Phase 4 Community Health Worker Respiratory Health Intervention Trial in Nepal
Summary
NIH has registered a Phase 4 clinical trial (NCT07540000) on ClinicalTrials.gov testing whether a community health volunteer-delivered multi-component program can improve lung health for people at risk of chronic respiratory diseases in Bhaktapur, Nepal. The 40-month study will enroll index participants and household members, with 11 research visits including spirometry, exhaled carbon monoxide measurements, blood pressure checks, and accelerometer monitoring. The intervention focuses on reducing tobacco smoke and air pollution exposure, preventing respiratory infections through vaccination and mask use, and encouraging safe physical activity.
What changed
A new clinical trial registration has been published on ClinicalTrials.gov for a community health worker-delivered respiratory health intervention study in Nepal. The trial will assess whether a multi-component program addressing tobacco smoke exposure, indoor and outdoor air pollution, respiratory infection prevention, and physical activity can improve lung health outcomes over approximately 40 months. Trial sponsors and investigators should ensure all required ClinicalTrials.gov disclosures are current, including registration within 21 days of study initiation and results reporting within 12 months of primary completion date per FDAAA 801 requirements.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
The INTERvening for LUNG Health Trial
Phase 4 NCT07540000 Kind: PHASE4 Apr 20, 2026
Abstract
This research study is being done to find out whether a community health volunteer-delivered, multi-component program can improve lung health for people at risk of chronic respiratory diseases (such as asthma or COPD) in Bhaktapur, Nepal. The program focuses on reducing tobacco smoke exposure, reducing indoor and outdoor air pollution exposure, preventing respiratory infections (including vaccination and mask use during viral seasons), and encouraging safe physical activity. The "index participant" is the main enrolled participant in the household who is randomized to the intervention or control arm.
The participant will be in the study for about 40 months and will have 11 research visits: one at baseline and then every 4 months through month 40. At visits, staff will do breathing tests (spirometry before and after an inhaled medicine), measure exhaled carbon monoxide, check blood pressure, measure height/weight at selected visits, and ask questions about symptoms, smoking, infections, vaccines, and quality of life. The participant will also wear an activity monitor (accelerometer) for 2 weeks at baseline and at follow-up visits. If individual is a household member (not the index participant), the participant may be asked to complete baseline and follow-up assessments every 4 months through month 40, will receive the influenza vaccine and will primarily be asked to use masks and handwashing during household respiratory illness episodes (only if the index participant is ra...
Conditions: Spirometry
Interventions: Community health worker-delivered multi-component respiratory health intervention
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.